Those with conditions susceptible to impaired exogenous lipid clearance due to decreased lipoprotein lipase activity (e.g., diabetes mellitus, pancreatitis, and renal failure); liver failure; or a history of hyperlipidemia, obesity, corticosteroid therapy, human immunodeficiency virus disease, or multisystem organ failure are at risk for hypertriglyceridemia during the administration of intravenous lipid emulsion [20,21]. This evidence concerns the gene LPL and kidney failure.